Rheumatology Therapeutics Market Share, Trends, Future Outlook, Analysis and Forecast 2023-2030 | AbbVie Inc., Amgen Inc., Eli Lilly

The global rheumatology therapeutics market is anticipated to grow at a CAGR of 3.2% during the forecast period (2023-2030). The growth of the rheumatology therapeutics market is primarily driven by the increased utilization of disease-modifying anti-rheumatic medicines (DMARDs) for targeted disease treatment. Recent steps in rheumatology have led to a diverse range of drug options available to rheumatologists, particularly for managing rheumatic joint disorders. The World Health Organization (WHO) reported that around 18 million individuals were living with rheumatoid arthritis globally in 2019. This condition predominantly affects women (70%) and those aged over 55 (55%).

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/rheumatology-therapeutics-market

One such condition, Polymyalgia rheumatica, can severely impair daily activities due to its flares of painful symptoms across multiple body areas An approval by the FDA for a steroid-free treatment for polymyalgia rheumatica marks a significant step in treatment. For instance, in March 2023, for sarilumab (Kevzara), an interleukin (IL) 6 receptor antagonist, gained FDA approval for individuals with polymyalgia rheumatica who have either failed glucocorticoid treatment or cannot tolerate its tapering.

Often, patients with psoriatic arthritis are not able not suspect a connection between their psoriasis skin symptoms and the joint pain, swelling and stiffness, resulting in delayed diagnosis and treatment. For instance, in January 2022, AbbVie released FDA-approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30% of patients with psoriasis. Ankylosing spondylitis (AS) is a chronic, inflammatory disease of the axial spine. Chronic back pain and progressive spinal stiffness are the most common features of this disease. For instance, in November 2021, Pfizer Inc. announced that the European Commission has approved XELJANZ® (tofacitinib) 5 mg twice daily for the treatment of adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.

Market Coverage

• The market number available for - 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Drug Type
o By Disease Indication
o By Category
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Merck & Co., Inc., Novartis AG, Pfizer Inc. and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Rheumatology Therapeutics Market Report Segment

By Drug Type

• Disease-modifying Anti-rheumatic Drugs
• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids
• Uric Acid Drugs
• Others

By Disease Indication

• Rheumatoid Arthritis
• Osteoarthritis
• Gout
• Psoriatic Arthritis
• Ankylosing Spondylitis

By Category

• Prescription
• Over-the-Counter (OTC)

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

A full report of Rheumatology Therapeutics Market available @ https://www.omrglobal.com/industry-reports/rheumatology-therapeutics-market

Global Rheumatology Therapeutics Market Report Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Aurinia Pharmaceuticals Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co.
• Eli Lilly
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Janssen Pharmaceuticals, Inc.
• Johnson & Johnson Private Ltd.
• Regeneron Pharmaceuticals Inc.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Related Report

https://ekz-crosstour.ch/news/der-weltweite-markt-fuer-molekulare-point-of-care-diagnostik-soll-bis-2030-56-milliarden-us-dollar-erreichen/141338/

https://www.somosxbox.com.mx/noticias-urgente/tamano-del-mercado-de-equipos-de-transmision-participacion-crecimiento-investigacion-y-pronostico-2022-2028/124401/

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.